# Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

> **NCT02865720** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 8 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** CINRYZE 500 U
- **DRUG:** CINRYZE 1000 U

## Key facts

- **NCT ID:** NCT02865720
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-08
- **Primary completion:** 2017-06-23
- **Final completion:** 2017-06-23
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02865720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02865720, "Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02865720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*